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cA Reassessment of Needs and Practice Patterns in Pharmacologic
Prophylaxis of Venous Thromboembolism Following Elective Major
Surgery
Quadan M, Polk HC Jr, Hohmann SF, et al. Ann Surg 2011;253:215-20.
Conclusion: Physician judgment is important in determining suscep-
tibility to venous thromboembolism (VTE) in patients after major abdom-
inal surgery.
Summary: There were an estimated 900,000 cases of VTE in hospi-
talized patients, in the U.S. in 2005, with 300,000 fatal (Heit JA, et al.
American Society of Hematology Annual Meeting Abstract 2005;106 ab-
stract 910). However, pulmonary embolism (PE) after major elective ab-
dominal surgery seems very uncommon. Opponents of a “one size fits all”
approach to VTE prophylaxis believe routine VTE prophylaxis increases cost
and compromises staff and facility resources to administer what is potentially
dangerous treatment for an infrequent event in certain categories of patients.
Trials of VTE prophylaxis use some VTE events as end points for efficacy,
such as calf vein thrombosis, that may not be clinically significant at least in
the short-term. In 2004, the Kentucky Surgical Care Improvement Project
found a very low rate of PE in 5285 elective specialty surgery patients: 15
PEs were detected in these patients, and none were fatal, despite erratic and
very limited use of VTE prophylaxis. The authors queried the University
Health System Consortium database from 2004 and also found a very low
rate of VTE complication in patients undergoing elective operations (Surg
2008;144:654-60). It is possible, however, that American College of Chest
Physicians (ACCP) recommendations may have altered practices of VTE
prophylaxis in elective surgical patients, and rates of fatal and nonfatal PE
could be influenced by changing indications for VTE prophylaxis. The
authors’ study was designed to assess and compare rates of VTE prophylaxis
and PE from an 18-month consecutive period in 2003 to 2004 to an
identical period of observation in 2007 to 2008. Their hope was to assess the
effect of the ACCP recommendations advocating an increase in VTE pro-
phylaxis.
The authors queried the University Health System Consortium data-
base comprising data from 123 academic teaching hospitals. They identified
patients undergoing colorectal resections, total hip replacement, total knee
replacement, and hysterectomies from two 18-consecutive month periods:
2003 to 2004 and 2007 to 2008. VTE rates ranged from 0.6% to 3.2% and
PE rates ranged from 0.28% to 1.09%. Use of VTE prophylaxis increased for
all procedures between 2003 to 2004 and 2007 to 2008, except for
hysterectomy. Comparing the two periods, the authors found VTE rates
were not significantly affected among patients who received pharmacologic
prophylaxis and actually decreased in patients who did not receive any
pharmacologic prophylaxis, despite an absence of significant change of
severity of illness in the patient populations.
Comment: The author’s arguments appear to be a step backward from
routine VTE prophylaxis to an approach where “the need for prophylaxis
would be assessed on an individual basis, based on retrospective data, expert
consensus, and clinical judgment.” What the authors have actually found is
that in a practice where VTE prophylaxis is encouraged and withheld only
for specific reasons, the rate of VTE complications, specifically fatal PE, is
low. It does not follow that the same results can be obtained with the
approach of withholding VTE prophylaxis unless one judges it to be specif-
ically required in individual cases.
Influence of Preceding Length of Anticoagulant Treatment and Initial
Presentation of Venous Thromboembolism on Risk of Recurrence
After Stopping Treatment: Analysis of Individual Participants’ Data
From Seven Trials
Boutitie F, Pinede L, Schulman S. BMJ 2011;342:d3036; doi:10.1136/
bmj.d3036.
Conclusion: Risk of recurrent venous thromboembolism (VTE) after
3 months of anticoagulation therapy is similar to longer courses of antico-
agulation. A higher risk of recurrence is present when the initial VTE event
is a proximal deep venous thrombosis (DVT) or pulmonary embolism (PE).
Summary: Randomized data indicate that at least 3 months of antico-
agulation is preferable to shorter periods to reduce recurrent VTE after an
initial VTE episode. Studies evaluating the optimal length of vitamin K
antagonist treatment after VTE have compared two lengths of treatment.
When only two lengths of treatment are compared, it is not possible to tell if
the superior length of treatment from one individual study is the overall
optimal length of treatment. The authors pooled data from seven individual
comparative trials using a spectrum of lengths of treatment for VTE. The
primary goal was to identify the shortest treatment length that most reduces
v
p
1220he risk of recurrent VTE after stopping treatment with vitamin a K antag-
nist. They also sought to determine the optimal length of anticoagulant
reatment with respect to specific subgroups at time of presentation VTE
proximal or distal DVT or PE) and whether thrombus recurrence was
nfluenced by a temporary risk factor or whether the VTE was unprovoked.
he seven studies comprised 2925 men and women with a first-time VTE
vent who did not have cancer. The primary end point was the first recurrent
enous VTE event after stopping anticoagulation during up to 24 months of
ollow-up. The pooled data indicated recurrence was lower after isolated
istal DVT then after proximal DVT (HR, 0.49; 95% CI, 0.34-0.71).
ecurrence was similar after PE and proximal DVT (HR, 1.19; 95% CI,
.87-1.63). Recurrence was lower after a VTE event associated with a
emporary risk factor than after an unprovoked VTE (HR, 0.55; 95% CI,
.41-0.74). Recurrence was similar if treatment was stopped at 3 months
ompared with 6 months or later (HR 1.19; 95% CI, 0.86-1.65). Recur-
ence was higher if anticoagulation was stopped at 1 or 1.5 months com-
ared with 3 months or later (HR, 1.52; 95% CI, 1.14-2.02). Overall, higher
ates of recurrence were associated with shorter durations of anticoagulation
nd were confined to the first 6 months after stopping vitamin K antagonist
herapy.
Comment: The analysis indicates patients with a VTE event who do
ot have an obvious indication for indefinite anticoagulation can stop
itamin K antagonist treatment after 3 months. Among the limitations of
his study were that D-dimer levels and vascular laboratory assessment of the
tatus of the venous thrombus at the end of anticoagulation were not
ncluded as potential variables influencing duration of anticoagulation.
erhaps patients with unprovoked VTE will, in the future, be better stratified
y additional variables to determine which patients will have a low risk of
ecurrence with only 3 months of treatment.
ilostazol Versus Aspirin for Secondary Prevention of Vascular Events
fter Stoke of Arterial Origin
amal AK, Naqvi I, Husain MR, et al. Stroke 2011;42:e382-4.
Conclusion: In Asian populations after an initial stroke, cilostazol is
uperior to aspirin in secondary prevention of stroke, myocardial infarction,
r vascular death.
Summary: This is a summary of a Cochrane Review. The review is
ased on the fact that aspirin for secondary prevention after stroke of arterial
rigin has been widely studied and prescribed. Cilostazol has been used for
econdary prevention in Asian populations with non-cardioembolic stroke
nd no clinically evident cardiac disease. The purpose of this review was to
etermine the relative effectiveness and safety of cilostazol compared with
spirin in the prevention of stroke and other vascular events in patients with
previous transient ischemic attack (TIA) or ischemic stroke of arterial
rigin.
The authors searched the Cochrane Stroke Group trials register, the
ochrane Central Register of Controlled Trials, and Embase (1980 to May
010) to identify ongoing, unpublished, and published studies relating to
he secondary prevention of vascular events with cilostazol vs aspirin in
atients with stroke of arterial origin. Only randomized controlled trials
omparing cilostazol with aspirin where participants were treated for at least
month and monitored systematically for development of vascular events
defined as stroke, myocardial infarction, or vascular death) were used for the
nalysis. Two independent reviewers selected trials for inclusion, assessed
rial quality, and extracted data. Treatment effect was determined by the
antel-Haenszel method.
The authors identified two trials from China and Japan with 3477
articipants with ischemic stroke of arterial origin. Trials were judged to be
f good quality. Cilostazol, when compared with aspirin, was associated with
significantly lower risk of the composite outcome of vascular events,
ncluding stroke, myocardial infarction, or vascular death (relative risk, 0.72;
5% CI, 0.57-0.91). The proportional benefit of cilostazol over aspirin on
he outcome of any hemorrhagic or ischemic stroke was 33% (95% CI,
4%-48%). Specifically, with respect to hemorrhagic stroke during follow-
p, cilostazol was associated with a risk reduction of 74% (95% CI 45%-87%)
ompared with aspirin. Patients receiving aspirin had more clinically de-
ected bleeding and more extracranial hemorrhage compared with cilostazol
relative risk, 0.74; 95% CI, 0.61-0.90). There were more minor adverse
ffects with cilostazol than aspirin, including headache, gastrointestinal
ntolerance, palpitation, dizziness, tachycardia, angina, and cardiac failure.
Comment: In the Asian population, at least from China and Japan,
ilostazol appears to be superior to aspirin in secondary prevention of
ascular events after a TIA or stroke. The results are even more dramatic in
reventing secondary stroke from intracranial hemorrhage. Cilostazol was
